Motley Fool Money cover image

Biotech Beat NVIDIA in 2025. Can It Do It Again?

Motley Fool Money

00:00

Gene and Cell Therapy Approvals Becoming Unpredictable

Karl cites Regenxbio's hold and explains why CBER gene therapies face stricter, inconsistent scrutiny now.

Play episode from 06:03
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app